358 related articles for article (PubMed ID: 29028645)
21. Multiplatform molecular test performance in indeterminate thyroid nodules.
Lupo MA; Walts AE; Sistrunk JW; Giordano TJ; Sadow PM; Massoll N; Campbell R; Jackson SA; Toney N; Narick CM; Kumar G; Mireskandari A; Finkelstein SD; Bose S
Diagn Cytopathol; 2020 Dec; 48(12):1254-1264. PubMed ID: 32767735
[TBL] [Abstract][Full Text] [Related]
22. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
23. Benign call rate and molecular test result distribution of ThyroSeq v3.
Ohori NP; Landau MS; Carty SE; Yip L; LeBeau SO; Manroa P; Seethala RR; Schoedel KE; Nikiforova MN; Nikiforov YE
Cancer Cytopathol; 2019 Mar; 127(3):161-168. PubMed ID: 30561907
[TBL] [Abstract][Full Text] [Related]
24. Molecular diagnostic testing and the indeterminate thyroid nodule.
Yip L
Curr Opin Oncol; 2014 Jan; 26(1):8-13. PubMed ID: 24225416
[TBL] [Abstract][Full Text] [Related]
25. Using molecular testing to improve the management of thyroid nodules with indeterminate cytology: an institutional experience with review of molecular alterations.
Glass RE; Marotti JD; Kerr DA; Levy JJ; Vaickus LJ; Gutmann EJ; Tafe LJ; Motanagh SA; Sorensen MJ; Davies L; Liu X
J Am Soc Cytopathol; 2022; 11(2):79-86. PubMed ID: 34627720
[TBL] [Abstract][Full Text] [Related]
26. The first Canadian experience with the Afirma® gene expression classifier test.
Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
[TBL] [Abstract][Full Text] [Related]
27. Clinical utility of a microRNA classifier in cytologically indeterminate thyroid nodules with RAS mutations: A multi-institutional study.
Tumati A; Egan CE; Lee-Saxton YJ; Marshall TE; Lee J; Jain K; Heymann JJ; Gokozan H; Azar SA; Schwarz J; Keutgen XM; Laird AM; Beninato T; Zarnegar R; Fahey TJ; Finnerty BM
Surgery; 2024 Jan; 175(1):234-240. PubMed ID: 37907382
[TBL] [Abstract][Full Text] [Related]
28. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
Yang Z; Zhang T; Layfield L; Esebua M
J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
[TBL] [Abstract][Full Text] [Related]
29. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.
Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL
Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079
[TBL] [Abstract][Full Text] [Related]
30. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
31. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
[TBL] [Abstract][Full Text] [Related]
32. Clinical performance of multiplatform mutation panel and microRNA risk classifier in indeterminate thyroid nodules.
Sistrunk JW; Shifrin A; Frager M; Bardales RH; Thomas J; Fishman N; Goldberg P; Guttler R; Grant E
J Am Soc Cytopathol; 2020; 9(4):232-241. PubMed ID: 32247769
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic performance of molecular testing in indeterminate (Bethesda III and IV) thyroid nodules with Hürthle cell cytology.
Raghunathan R; Longstaff XR; Hughes EG; Li SJ; Sant VR; Tseng CH; Rao J; Wu JX; Yeh MW; Livhits MJ
Surgery; 2024 Jan; 175(1):221-227. PubMed ID: 37926582
[TBL] [Abstract][Full Text] [Related]
34. Clinical use of Molecular Data in Thyroid Nodules and Cancer.
Alzahrani AS
J Clin Endocrinol Metab; 2023 Oct; 108(11):2759-2771. PubMed ID: 37200449
[TBL] [Abstract][Full Text] [Related]
35. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
36. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules.
Eszlinger M; Hegedüs L; Paschke R
Best Pract Res Clin Endocrinol Metab; 2014 Aug; 28(4):545-57. PubMed ID: 25047205
[TBL] [Abstract][Full Text] [Related]
37. Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?
Kloos RT; Reynolds JD; Walsh PS; Wilde JI; Tom EY; Pagan M; Barbacioru C; Chudova DI; Wong M; Friedman L; LiVolsi VA; Rosai J; Lanman RB; Kennedy GC
J Clin Endocrinol Metab; 2013 Apr; 98(4):E761-8. PubMed ID: 23476074
[TBL] [Abstract][Full Text] [Related]
38. Thyroid cytology smear slides: An untapped resource for ThyroSeq testing.
Nikiforova MN; Lepe M; Tolino LA; Miller ME; Ohori NP; Wald AI; Landau MS; Kaya C; Malapelle U; Bellevicine C; Troncone G; Nikiforov YE; Baloch Z
Cancer Cytopathol; 2021 Jan; 129(1):33-42. PubMed ID: 32697051
[TBL] [Abstract][Full Text] [Related]
39. A Triumvirate:: Correlating Thyroid Cytopathology, Molecular Testing, and Histopathology.
Velez Torres JM; Tjendra Y; Kerr DA
Surg Pathol Clin; 2023 Mar; 16(1):1-14. PubMed ID: 36739157
[TBL] [Abstract][Full Text] [Related]
40. Next-Generation Sequencing Identifies a Highly Accurate miRNA Panel That Distinguishes Well-Differentiated Thyroid Cancer from Benign Thyroid Nodules.
Mazeh H; Deutch T; Karas A; Bogardus KA; Mizrahi I; Gur-Wahnon D; Ben-Dov IZ
Cancer Epidemiol Biomarkers Prev; 2018 Aug; 27(8):858-863. PubMed ID: 30049841
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
